[
  {
    "ts": null,
    "headline": "Top Stock Reports for Apple, Eli Lilly & Visa",
    "summary": "Apple's strong Services growth, Eli Lilly's GLP-1 momentum, and Visa's digital expansion headline today's top stock reports.",
    "url": "https://finnhub.io/api/news?id=61d183e4eb7f53c15fe6741254730a10161bf14157b6958dd1bf953601abb40f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760386500,
      "headline": "Top Stock Reports for Apple, Eli Lilly & Visa",
      "id": 137074232,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Apple's strong Services growth, Eli Lilly's GLP-1 momentum, and Visa's digital expansion headline today's top stock reports.",
      "url": "https://finnhub.io/api/news?id=61d183e4eb7f53c15fe6741254730a10161bf14157b6958dd1bf953601abb40f"
    }
  },
  {
    "ts": null,
    "headline": "AZN Strikes Drug Pricing Deal With Trump, Gets 3-Year Tariff Reprieve",
    "summary": "AstraZeneca secures a three-year tariff break after striking a landmark U.S. deal to cut drug prices and expand its domestic manufacturing.",
    "url": "https://finnhub.io/api/news?id=1480f66d706d835623c6a351a69c2d21b03fe4681b3b19910e0dc7f1cd409960",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760377200,
      "headline": "AZN Strikes Drug Pricing Deal With Trump, Gets 3-Year Tariff Reprieve",
      "id": 137070417,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "AstraZeneca secures a three-year tariff break after striking a landmark U.S. deal to cut drug prices and expand its domestic manufacturing.",
      "url": "https://finnhub.io/api/news?id=1480f66d706d835623c6a351a69c2d21b03fe4681b3b19910e0dc7f1cd409960"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly & Co. stock underperforms Monday when compared to competitors",
    "summary": "Eli Lilly & Co. stock underperforms Monday when compared to competitors",
    "url": "https://finnhub.io/api/news?id=414cbb373517c6abcaf2fe8b0794a1623601082532344d72b8e6b204eda84b71",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760373060,
      "headline": "Eli Lilly & Co. stock underperforms Monday when compared to competitors",
      "id": 137077423,
      "image": "",
      "related": "LLY",
      "source": "MarketWatch",
      "summary": "Eli Lilly & Co. stock underperforms Monday when compared to competitors",
      "url": "https://finnhub.io/api/news?id=414cbb373517c6abcaf2fe8b0794a1623601082532344d72b8e6b204eda84b71"
    }
  },
  {
    "ts": null,
    "headline": "New US biotech hubs showing potential amid onshoring request",
    "summary": "While established US biotech hubs may still rule the roost, emerging competitors are looking to grab a larger slice of the market.",
    "url": "https://finnhub.io/api/news?id=de77e07e9f38aa41868ba917d2e511b15e0cd2fbbb726d8aed94105baf42138a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760367424,
      "headline": "New US biotech hubs showing potential amid onshoring request",
      "id": 137068535,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "While established US biotech hubs may still rule the roost, emerging competitors are looking to grab a larger slice of the market.",
      "url": "https://finnhub.io/api/news?id=de77e07e9f38aa41868ba917d2e511b15e0cd2fbbb726d8aed94105baf42138a"
    }
  },
  {
    "ts": null,
    "headline": "Down 44%, Should You Buy the Dip on Viking Therapeutics?",
    "summary": "The company is readying to take on pharma giants Novo Nordisk and Eli Lilly.",
    "url": "https://finnhub.io/api/news?id=0ab404211f3e211bb9047ec245e46b090d8f50efcc1cdcb1b2405f030f5edaf1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760364900,
      "headline": "Down 44%, Should You Buy the Dip on Viking Therapeutics?",
      "id": 137068536,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The company is readying to take on pharma giants Novo Nordisk and Eli Lilly.",
      "url": "https://finnhub.io/api/news?id=0ab404211f3e211bb9047ec245e46b090d8f50efcc1cdcb1b2405f030f5edaf1"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly Omvoh Demonstrates Sustained Long-Term Benefits in Ulcerative Colitis Up to Four Years",
    "summary": "Eli Lilly and Company (NYSE:LLY) is one of the best growth stocks to buy now. On October 7, Eli Lilly and Company announced new data from the LUCENT-3 Phase 3 open-label extension study demonstrating that its drug, Omvoh (mirikizumab-mrkz), is the first and only interleukin-23p19 (IL-23p19) antagonist to provide patients with moderately to severely active […]",
    "url": "https://finnhub.io/api/news?id=ab009810eb939af3513b395109d7750f1c3d38c3e080d01795c8397d74b0a8ff",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760362127,
      "headline": "Eli Lilly Omvoh Demonstrates Sustained Long-Term Benefits in Ulcerative Colitis Up to Four Years",
      "id": 137068537,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly and Company (NYSE:LLY) is one of the best growth stocks to buy now. On October 7, Eli Lilly and Company announced new data from the LUCENT-3 Phase 3 open-label extension study demonstrating that its drug, Omvoh (mirikizumab-mrkz), is the first and only interleukin-23p19 (IL-23p19) antagonist to provide patients with moderately to severely active […]",
      "url": "https://finnhub.io/api/news?id=ab009810eb939af3513b395109d7750f1c3d38c3e080d01795c8397d74b0a8ff"
    }
  },
  {
    "ts": null,
    "headline": "Roche's Elecsys® pTau181 becomes the only FDA-cleared blood test for use in primary care to rule out Alzheimer's-related amyloid pathology",
    "summary": "Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the United States Food and Drug Administration (FDA) has cleared its Elecsys pTau181 test, the only blood-based biomarker (BBM) test indicated as an aid in the initial assessment for Alzheimer's disease and other causes of cognitive decline in the primary-care setting. The Elecsys pTau181 test is intended for patients ages 55 and older presenting with signs, symptoms or complaints of cognitive decline. It measures phosphorylated Tau (pTau)",
    "url": "https://finnhub.io/api/news?id=fd144c73c5bb43f61521f055d989be377ddfa914cc9cfc4c022ee5a2f40d87e0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760360400,
      "headline": "Roche's Elecsys® pTau181 becomes the only FDA-cleared blood test for use in primary care to rule out Alzheimer's-related amyloid pathology",
      "id": 137066791,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the United States Food and Drug Administration (FDA) has cleared its Elecsys pTau181 test, the only blood-based biomarker (BBM) test indicated as an aid in the initial assessment for Alzheimer's disease and other causes of cognitive decline in the primary-care setting. The Elecsys pTau181 test is intended for patients ages 55 and older presenting with signs, symptoms or complaints of cognitive decline. It measures phosphorylated Tau (pTau)",
      "url": "https://finnhub.io/api/news?id=fd144c73c5bb43f61521f055d989be377ddfa914cc9cfc4c022ee5a2f40d87e0"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly: The Rally Has More Room To Run (Rating Upgrade)",
    "summary": "Eli Lilly: The Rally Has More Room To Run (Rating Upgrade)",
    "url": "https://finnhub.io/api/news?id=b07f28a4c5a373a022e4dab1c554cc196af7584f5cf34ec190099617f70af3bc",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760352679,
      "headline": "Eli Lilly: The Rally Has More Room To Run (Rating Upgrade)",
      "id": 137067545,
      "image": "",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=b07f28a4c5a373a022e4dab1c554cc196af7584f5cf34ec190099617f70af3bc"
    }
  },
  {
    "ts": null,
    "headline": "Lilly to present new clinical data for Verzenio (abemaciclib) and multiple novel pipeline programs at the 2025 European Society for Medical Oncology (ESMO) Annual Meeting",
    "summary": "Eli Lilly and Company (NYSE: LLY) today announced that new data from across its oncology portfolio and pipeline will be presented at the European Society for Medical Oncology (ESMO) Annual Meeting, taking place October 17-21 in Berlin, Germany. These presentations highlight the breadth of Lilly's portfolio across treatment modalities and tumor types.",
    "url": "https://finnhub.io/api/news?id=ad4d0f8e3d0577e76df106f7231349ed9d184e9947ea9d52ad9ff0f35b2b37f1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760352300,
      "headline": "Lilly to present new clinical data for Verzenio (abemaciclib) and multiple novel pipeline programs at the 2025 European Society for Medical Oncology (ESMO) Annual Meeting",
      "id": 137066284,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly and Company (NYSE: LLY) today announced that new data from across its oncology portfolio and pipeline will be presented at the European Society for Medical Oncology (ESMO) Annual Meeting, taking place October 17-21 in Berlin, Germany. These presentations highlight the breadth of Lilly's portfolio across treatment modalities and tumor types.",
      "url": "https://finnhub.io/api/news?id=ad4d0f8e3d0577e76df106f7231349ed9d184e9947ea9d52ad9ff0f35b2b37f1"
    }
  }
]